New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 27, 2012
10:34 EDTACADAcadia jumps over 150% following positive trial results
Acadia Pharmaceuticals surged over 150% in mid-morning trading after the company said its Pimavanserin drug for Parkinson's disease succeeded in meeting the primary goal and key secondary goals of a Phase III trial. In the study, which evaluated the efficacy, tolerability and safety of Pimavanserin in patients with Parkinson's disease psychosis, or PDP, Acadia said Pimavanserin met the primary endpoint of the trial by demonstrating highly significant antipsychotic efficacy as measured using the 9-item SAPS-PD scale. In addition, the drug met the secondary endpoint for motoric tolerability and clinical benefits were observed in all exploratory efficacy measures with significant improvements in nighttime sleep, daytime wakefulness and caregiver burden. Roger G. Mills, M.D., Acadia's EVP of Development, commented that "benefits of Pimavanserin were seen by patients, caregivers and investigators, as well as the independent raters." Acadia said it will continue ongoing preparations for a confirmatory Phase III trial, which will use the same design. Acadia is trading up $3.54, or 153.48%, to $5.82 in mid-morning trading.
News For ACAD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 28, 2015
07:19 EDTACADACADIA price target raised to $50 from $42 at Jefferies
Jefferies raised its price target for ACADIA shares to $50 after increasing its Nuplazid sales estimates in Parkinson's disease psychosis. The firm believes Nuplazidís efficacy and safety profile could lead to a strong launch and keeps a Buy rating on ACADIA.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use